

VolitionRx

16:33 08 May 2019

VolitionRx boosts cash reserves in 1Q

VolitionRx Limited (NYSE AMERICAN:VNRX) on Wednesday announced that it ended its first quarter with \$16.2 million in cash and cash equivalents, growing its cash reserves.

The life-sciences company noted that it had \$13.4 million in cash and cash equivalents at the end of 2018. In addition, VolitionRx said it continues to manage cash carefully with a cash burn of \$3.9 million in the first quarter, which ended March 31.

WATCH: VolitionRx well positioned as it enters Q2 after strengthening balance sheet

"During the first quarter 2019, we further strengthened our balance sheet with existing investors exercising \$6.7 million in aggregate amount of outstanding warrants to purchase shares of our common stock," said CEO Cameron Reynolds.

He added that "subsequent to the ending of the quarter, a further \$5 million in warrants were exercised for cash, making a total of \$11.7 million in warrants exercised this year."

The company has designed routine Nu.Q blood-based diagnostic tests to screen for colorectal and prostate cancers that reduce the need for more invasive colonoscopies and biopsies.

VolitionRx's stock rose 2.15% Wednesday to close at \$3.33 a share.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Price: US\$4.16

Market Cap: US\$164770000M

1 Year Share Price Graph



August 2018 February 2019 August 2019

Share Information

Code: VNRX

Listing: NYSEMKT

52 week	High	Low
	\$4.65	\$1.67

Sector: Pharma & Biotech

Website: volitionrx.com

Company Synopsis:

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.